Published in:
Open Access
01-12-2015 | Original research
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Authors:
Hiroaki Kurihara, Akinobu Hamada, Masayuki Yoshida, Schuichi Shimma, Jun Hashimoto, Kan Yonemori, Hitomi Tani, Yasuji Miyakita, Yousuke Kanayama, Yasuhiro Wada, Makoto Kodaira, Mayu Yunokawa, Harukaze Yamamoto, Chikako Shimizu, Kazuhiro Takahashi, Yasuyoshi Watanabe, Yasuhiro Fujiwara, Kenji Tamura
Published in:
EJNMMI Research
|
Issue 1/2015
Login to get access
Abstract
Background
The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with 64Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab.
Methods
PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after the injection of approximately 130 MBq of the probe 64Cu-DOTA-trastuzumab. Radioactivity in metastatic brain tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2 specificity of 64Cu-DOTA-trastuzumab.
Results
Metastatic brain lesions could be visualized by 64Cu-DOTA-trastuzumab PET in all of five cases, which might indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of 64Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.
Conclusions
Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer.